JP2015510883A5 - - Google Patents

Download PDF

Info

Publication number
JP2015510883A5
JP2015510883A5 JP2014561022A JP2014561022A JP2015510883A5 JP 2015510883 A5 JP2015510883 A5 JP 2015510883A5 JP 2014561022 A JP2014561022 A JP 2014561022A JP 2014561022 A JP2014561022 A JP 2014561022A JP 2015510883 A5 JP2015510883 A5 JP 2015510883A5
Authority
JP
Japan
Prior art keywords
aureus
vaccine
infection
biofilm
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014561022A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015510883A (ja
JP6204930B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/029053 external-priority patent/WO2013134225A1/en
Publication of JP2015510883A publication Critical patent/JP2015510883A/ja
Publication of JP2015510883A5 publication Critical patent/JP2015510883A5/ja
Application granted granted Critical
Publication of JP6204930B2 publication Critical patent/JP6204930B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014561022A 2012-03-05 2013-03-05 多価ワクチンによる黄色ブドウ球菌感染症からの保護 Expired - Fee Related JP6204930B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261606750P 2012-03-05 2012-03-05
US61/606,750 2012-03-05
PCT/US2013/029053 WO2013134225A1 (en) 2012-03-05 2013-03-05 Multivalent vaccine protection from staphylococcus aureus infection

Publications (3)

Publication Number Publication Date
JP2015510883A JP2015510883A (ja) 2015-04-13
JP2015510883A5 true JP2015510883A5 (enExample) 2016-04-21
JP6204930B2 JP6204930B2 (ja) 2017-09-27

Family

ID=49117246

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014561022A Expired - Fee Related JP6204930B2 (ja) 2012-03-05 2013-03-05 多価ワクチンによる黄色ブドウ球菌感染症からの保護

Country Status (6)

Country Link
US (2) US9265820B2 (enExample)
EP (1) EP2822582B1 (enExample)
JP (1) JP6204930B2 (enExample)
CA (1) CA2865620A1 (enExample)
ES (1) ES2642892T3 (enExample)
WO (1) WO2013134225A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513305B2 (en) 2007-05-14 2013-08-20 Research Foundation Of State University Of New York Induction of a physiological dispersion response in bacterial cells in a biofilm
WO2015171693A1 (en) * 2014-05-06 2015-11-12 Virginia Commonwealth University A new target for firmicutes and related bacteria: the prp protease
EP3532070A1 (en) 2016-10-26 2019-09-04 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
CN110461343A (zh) * 2017-03-31 2019-11-15 阿塞尔公司 用于保护或治疗细菌感染患者的具有杀菌或抑菌特性的细胞外基质组合物
CA3084954A1 (en) 2017-12-05 2019-06-13 BioPlx, Inc. Methods and compositions to prevent microbial infection
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
JP2024504640A (ja) * 2021-01-15 2024-02-01 ユニバーシティ オブ ロチェスター Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ抗原系核酸ワクチン
CN112940987B (zh) * 2021-04-10 2022-10-14 福建省农业科学院畜牧兽医研究所 一株兔金黄色葡萄球菌及其在制备灭活疫苗中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
US8173363B2 (en) * 2002-08-20 2012-05-08 Novartis Vaccines And Diagnostics, Inc. Random transposon insertion in Staphylococcus aureus and use thereof to identify essential genes
MY148405A (en) * 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
EP2176662B1 (en) * 2007-07-30 2012-03-28 The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And Behalf Of Methods and devices for the detection of biofilm
CA2738793A1 (en) * 2008-09-30 2010-04-08 University Of Maryland, Baltimore Protective vaccine against staphylococcus aureus biofilms comprising cell wall-associated immunogens

Similar Documents

Publication Publication Date Title
JP6204930B2 (ja) 多価ワクチンによる黄色ブドウ球菌感染症からの保護
RU2020133461A (ru) Предотвращение, разрушение и обработка биопленки лизином бактериофага
Gomes et al. Control of bovine mastitis: old and recent therapeutic approaches
RU2018107249A (ru) Применение лизина для восстановления/увеличения антибактериальной активности антибиотиков в присутствии легочного сурфактанта, который ингибирует указанные антибиотики
Brunel et al. Multidrug resistant (or antimicrobial-resistant) pathogens-alternatives to new antibiotics?
NZ612315A (en) Compositions for immunising against staphylococcus aureus
JP2017519768A5 (enExample)
FI3006038T3 (fi) Oritavansiinin yksittäisannokset bakteeri-infektion hoitoon tai ehkäisyyn
JP2012501349A5 (enExample)
EP2344189B1 (en) Protective vaccine against staphylococcus aureus biofilms comprising cell wall-associated immunogens
WO2013032964A1 (en) Compositions and methods for preventing and treating biofilms
Gelalcha et al. Antimicrobial usage for the management of mastitis in the USA: impacts on antimicrobial resistance and potential alternative approaches
EA202290048A1 (ru) Лекарственное средство и его применение для лечения бактериальных инфекций, связанных с биопленкой
Malu et al. Topical use of citric acid for wound bed preparation
PH12019500242A1 (en) 9-aminomethyl minocycline compounds and uses thereof
MX366894B (es) Composiciones antimicrobianas y métodos para su producción.
WO2013042140A2 (en) Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement
JP2008526848A (ja) 黄色ブドウ球菌感染を治療する方法
JP2018521143A5 (enExample)
JP2016510749A5 (enExample)
BR112021019884A2 (pt) Método de tratamento e prevenção de infecções ósseas e articulares
RU2200575C2 (ru) Способ лечения гнойных инфекций
Overcash et al. 470. Treatment of acute bacterial skin and skin structure infections (ABSSSI) in patients with significant drug abuse: outcomes from global phase 3 studies of delafloxacin (DLX)
Rajani et al. Looking Beyond Antimicrobials: Newer Concepts and Technologies
RU2202366C2 (ru) Способ лечения гнойных инфекций